| Name | Title | Contact Details |
|---|---|---|
Ash Tengshe |
Senior Vice President and Chief Product and Technology Officer | Profile |
Paul Donnelly |
DevOps Lead and Security Officer | Profile |
The Y: Were for youth development, healthy living, and social responsibility
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. FibroGen’s research team is committed to discovering novel therapies in areas of major unmet medical need. Our goal is to continue to provide pipeline candidates supported by rigorous data in well-characterized therapeutic settings. All of FibroGen`s therapeutic candidates have been internally developed based on FibroGen`s pioneering research in two important areas of biology, hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF).
The American Association for Thoracic Surgery is an international organization of over 1,500 of the worlds foremost cardiothoracic surgeons representing 41 countries. The mission of the AATS is to promote scholarship, innovation, and leadership in tho...
Danube Pharmaeuticals, Inc., is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Paradigm Health Plans is the industry leader in creating self-funded value-based benefit designs for a total solution for your workforce. Founded in 2007, Paradigm has been partnering with businesses nationally to empower employers and their workforce to actively manage their healthcare costs.